Castle Biosciences Inc at Credit Suisse Healthcare Conference Transcript
For our next presentation, we have Castle Biosciences. Representing Castle is Derek Maetzold, CEO. The floor is yours, Derek.
Thank you, [Dam]. And thank you, Credit Suisse, for the invitation to come and have a conversation about Castle Biosciences.
So I'm going to run through some top line of our second quarter -- our third quarter earnings release a couple of weeks ago and then move into kind of a broader business conversation where Castle is today and where we think we're going to go tomorrow.
Disclaimer and forward-looking statements. So -- we had an excellent third quarter performance from my perspective. We saw both test report volume and revenue grow 57%, 58%, respectively over the respective quarters in 2021. So nice solid performance from the team in the third quarter.
On an adjusted gross margin perspective, we are coming in at 76.2% for the third quarter, down from 80%, but that really reflects scaling up in terms of test
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
